Mitophagy plays a noticeable role in neurodegenerative disorders (Palikaras and Tavernarakis, 2012), such as Alzheimers (Ye et al., 2015), Parkinsons (Ryan et al., 2015), and Huntingtons diseases (Khalil et al., 2015)
This weight loss also provides the patient with increased energy levels
Its potential to modulate metabolic and neuroprotective pathways offers hope for the development of new therapies that could improve the prognosis of patients with both diseases
found that GLP-1 receptor agonist use, compared with initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors, was associated with a lower risk of composite MALOs (aHR: 0.84, 95%CI: 0.74-0.94), including specifically lower occurrence of liver decompensation (aHR: 0.83) and all-cause mortality (aHR: 0.84) [56]